Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > POTENTIAL HOME CANCER TREATMENT
View:
Post by Tarbaby on Aug 21, 2024 11:51am

POTENTIAL HOME CANCER TREATMENT

Roger states that...pending GLP toxicology studies of Rutherrin and regulatory approval... they plan to start these trials.
Does this mean that toxicology of Rutherrin instilled by iv  has not yet been proven safe..?
Comment by Dumbeldorfwhite on Aug 21, 2024 11:59am
No been saying that for literally years, but again everyone here just turns a blind eye. They can't do human trials without it, and they have been saying pending GLP toxicology for probably 2-3 years now. Just more Petri dish fluff. Clearly the market doesn't care much.
Comment by Tarbaby on Aug 21, 2024 12:12pm
THIS IS VITAL ...1 Can Rutherrin safely  be taken by mouth or by IV...or  2. can it be instilled into the colon for colorectal cancer treatment which is a huge potential market. Or 3. Can it be injected directly into a solid tumour ? Or are toxicology studies still pending on these questions.?
Comment by menoalittle on Aug 21, 2024 12:58pm
Just think for a minute or two about the implications (and potential) of this alone: It's been proven that it can (very safely) be instilled into the bladder. The colon is very safely prepped (cleaned) for a colonoscopy. Proceed with an enema using a prescribed about of Rutherrin. Hold as long as possible for maximum absorption of Rutherrin. Take the prescribed dose of ...more  
Comment by Dumbeldorfwhite on Aug 21, 2024 3:46pm
That's factually not correct TLD1433 and Rutherrin are different drugs buddy
Comment by DJDawg on Aug 21, 2024 12:17pm
That is always the wording. It is safe but you have to do a lot of work on the animal models to figure out dosing and then extrapolate to humans. One background hope that I have is the mostly quiet Dr. Mandel. I've read his papers and he is first rate researcher. He would not be involved in the day to day of clinical trials so I would hope he has been doing good labwork on an ongoing basis ...more  
Comment by Tarbaby on Aug 21, 2024 12:30pm
Thanks DJDAWG..you state.. it is safe.. Do you mean that toxicology has been done? I dont see that statement on their website. Roger MUST clarify this. Once he does the stock price will surely jump.
Comment by DJDawg on Aug 21, 2024 12:36pm
What I mean is that they have produced lots of animal data and no reported adverse effects that would preclude human trials.
Comment by Tarbaby on Aug 21, 2024 12:50pm
Thanks again for your info but the company MUST clarify the toxicology matter before I will buy more stock. Others likely feel the same. Once they get regulatory approval..Wow...rocket time.!
Comment by menoalittle on Aug 21, 2024 1:00pm
Hey tarbaby... Try giving a little bit of thought for a few minutes to that last post of mine.
Comment by Tarbaby on Aug 21, 2024 1:13pm
Thanks Meno..Agreed the HUGE  potential might be there for treating colon cancer. Its number 2 in cancer deaths... But the colon absorbs unlike the bladder. So safety in the bladder might not assure safety in the colon. Unless toxicology is proven safe for human use. Lets go Roger..
Comment by Dumbeldorfwhite on Aug 21, 2024 3:48pm
It's not idk how many times I can say it. No it is not proven safe for humans, TLD 1433 was not rutherrin
Comment by DJDawg on Aug 21, 2024 3:57pm
Proven safe is a tricky wording. Yes. DDFW is correct has not proven safe in humans. All data provided to date suggests that it is safe in animal models that are used as a proxy. The process involves giving the drug to animals and measuring a million parameters to see if any suggestion of "toxicity". They have been doing this for a while and so far all reports are good but it is not ...more  
Comment by Tarbaby on Aug 21, 2024 4:51pm
Thanks DJ..that clarifies things a lot. But why dont they try it instilled inside a colon. Or maybe they have. If it worked there then colon cancer and bladder cancer cover a huge need..and worth billions and big benefit to society..
Comment by Galaxym31 on Aug 21, 2024 4:27pm
Cancer is not safe for any mammals .
Comment by CancerSlayer on Aug 21, 2024 6:25pm
Rutherrin & TLD 1433 are practically twins from a biological safety profile imo.  Keep in mind, Ruthenium/TLD 1433 closely mimics its relative, iron.  This enables it to have a high "affinity for transferrin" (a natural transporter of iron in the body), which is one of the core reasons for its low in vivo toxicity... as evidenced thus far in our current NMIBC study.    ...more  
Comment by wildbird1 on Aug 22, 2024 7:48am
Excellent post CancerSlayer... To complement your post..In the Feb23,2015 PressRelease...  2015-02-23 | Theralase Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells | TSXV:TLT | Press Release TLT said'' Rutherrin is able to provide 300% more payload of TLD-1433 to the cancer cell than TLD-1433 ...more  
Comment by menoalittle on Aug 22, 2024 9:00am
Don't forget to keep colon cancer near the top of that future big revenue maker list.  It has astonishingly huge potential not only for cancer treatment, but given Rutherrin's highly likely safety profile and ease of use (and activation with Metformin,) perhaps also a nice revenue stream for colon cancer prevention after a few "suspicious" polyp are removed in a routine ...more  
Comment by CancerSlayer on Aug 22, 2024 2:07pm
Nice post wildbird1... And imagine the potential veterinary applications.  There are almost as many pet owners/lovers as there are people...And perhaps animal model testing in rats will be more translatable to dogs, making both dog owners & PETA folks happy ; ).
Comment by Johnandrose22 on Aug 22, 2024 5:10pm
10 years ago this company caught my interest, imagination and enthusiasm with the introduction of TLD 1433 and its extraordinary promise. Now, with the company's recent NR, my feelings are renewed with the possibilities of Rutherin and its applications. In the spirit of imagination, just a question to the board. Given the apparent MOA of Rutherin/ Metformin,  Could the company run a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250